Barclays PLC Has $288,000 Stake in Cabaletta Bio, Inc. (NASDAQ:CABA)

Barclays PLC raised its position in Cabaletta Bio, Inc. (NASDAQ:CABA) by 48.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 61,130 shares of the company’s stock after purchasing an additional 19,891 shares during the quarter. Barclays PLC owned 0.13% of Cabaletta Bio worth $288,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Walleye Capital LLC grew its holdings in shares of Cabaletta Bio by 111.6% in the 3rd quarter. Walleye Capital LLC now owns 401,982 shares of the company’s stock valued at $1,897,000 after acquiring an additional 212,025 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Cabaletta Bio in the 3rd quarter valued at about $3,150,000. E Fund Management Co. Ltd. grew its holdings in shares of Cabaletta Bio by 1,610.1% in the 2nd quarter. E Fund Management Co. Ltd. now owns 286,424 shares of the company’s stock valued at $2,142,000 after acquiring an additional 269,675 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Cabaletta Bio by 490.2% in the 3rd quarter. XTX Topco Ltd now owns 87,455 shares of the company’s stock valued at $413,000 after acquiring an additional 72,638 shares in the last quarter. Finally, Victory Capital Management Inc. grew its holdings in Cabaletta Bio by 70.7% during the second quarter. Victory Capital Management Inc. now owns 634,217 shares of the company’s stock worth $4,744,000 after purchasing an additional 262,594 shares during the period.

Cabaletta Bio Stock Performance

Shares of NASDAQ:CABA opened at $2.40 on Monday. The company has a fifty day moving average of $3.10 and a 200-day moving average of $4.75. The company has a market capitalization of $117.30 million, a PE ratio of -1.12 and a beta of 2.46. Cabaletta Bio, Inc. has a 52-week low of $1.76 and a 52-week high of $26.35.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. UBS Group assumed coverage on Cabaletta Bio in a report on Thursday, October 10th. They set a “buy” rating and a $10.00 price target for the company. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a report on Friday, November 15th. TD Cowen upgraded Cabaletta Bio to a “strong-buy” rating in a report on Friday, November 29th. Evercore ISI downgraded shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and dropped their price target for the company from $15.00 to $6.00 in a research report on Friday, December 20th. Finally, Wells Fargo & Company downgraded shares of Cabaletta Bio from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $12.00 to $6.00 in a research report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $24.38.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.